Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Study of ALX148 in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma

Next Previous
X
Search
Trial Profile

A Phase 2/3 Study of ALX148 in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 20 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evorpacept (Primary) ; Paclitaxel (Primary) ; Ramucirumab (Primary) ; Trastuzumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms ASPEN-06
  • Sponsors ALX Oncology

    • Most Recent Events

    • 18 Dec 2024 According to a ALX Oncology media release, data from the study will be presented as oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 - 25, 2025.
    • 08 Aug 2024 According to a ALX Oncology media release, updated results of ASPEN-06 Phase 2 clinical trial are expected in 1H 2025.
    • 08 Aug 2024 According to a ALX Oncology media release, Phase 2 clinical trial readout in patients with previously treated HER2-positive advanced gastric cancer is a significant growth milestone for the Company.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top